These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 30855175)

  • 1. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
    Ren J; Asche CV; Shou Y; Galaznik A
    J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA.
    Morrison VA; Bell JA; Hamilton L; Ogbonnaya A; Shih HC; Hennenfent K; Eaddy M; Shou Y; Galaznik A
    Future Oncol; 2018 Oct; 14(25):2627-2642. PubMed ID: 29911900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Gatwood J; Masaquel A; Fox D; Sheinson D; James C; Li J; Hossain F; Ross R
    J Med Econ; 2024; 27(1):738-745. PubMed ID: 38686393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
    Mounié M; Costa N; Conte C; Petiot D; Fabre D; Despas F; Lapeyre-Mestre M; Laurent G; Savy N; Molinier L
    J Med Econ; 2020 Mar; 23(3):235-242. PubMed ID: 31876205
    [No Abstract]   [Full Text] [Related]  

  • 8. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
    Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
    Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
    Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
    Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study.
    Zheng W; Liu M; Guan L; Wang S
    Cancer Med; 2024 Apr; 13(8):e7120. PubMed ID: 38629251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
    Tsutsué S; Tobinai K; Yi J; Crawford B
    PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
    Matasar M; Sanchez Alvarez J; Parisé H; Zuk E; Di Maio D; Shapouri S; Kim E; Lin SW
    J Med Econ; 2024; 27(1):766-776. PubMed ID: 38712895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
    J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with
    Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y
    Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.
    Khor S; Beca J; Krahn M; Hodgson D; Lee L; Crump M; Bremner KE; Luo J; Mamdani M; Bell CM; Sawka C; Gavura S; Sullivan T; Trudeau M; Peacock S; Hoch JS
    BMC Cancer; 2014 Aug; 14():586. PubMed ID: 25117912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
    Dürig J; Uhlig J; Gerhardt A; Ritter M; Hapke G; Heßling J; Staib P; Wolff F; Krumm K; von Weikersthal LF
    Cancer Med; 2023 Feb; 12(3):2739-2751. PubMed ID: 36017743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.